

AlphaVax Hires New Medical Director

Durham, N.C.-- AlphaVax, Inc. announced today that Jeffrey D. Chulay, M.D. will join the company as medical director on February 1. Dr. Chulay is currently principal clinical program head in clinical development in HIV and Opportunistic Infections at GlaxoSmithKline in Research Triangle Park, N. C. He previously worked for the U.S. Army Research Institute for Infectious Disease (USAMRIID) and Walter Reed Army Institute for Research (WRAIR) in Maryland.

"Jeff Chulay is an exceptional addition to our management team," said Peter F. Young, AlphaVax president and CEO . "I know Jeff's capabilities in clinical research from my own personal experience. His background in immunology and virological medicine is directly relevant to our company's growth, and he will be invaluable as we, and our partners, begin moving products based on our vaccine technology into clinical trials. Jeff is a seasoned practitioner of clinical research. His successful track record in product development is combined with expertise in infectious disease, and he is already familiar with the AlphaVax vaccine vector system from his scientific career with the military."

Prior to joining Burroughs Wellcome in 1994, Dr. Chulay served as Chief of the Department of Immunology at WRAIR and subsequently as Chief of the Virology Division at USAMRIID. He earned his medical degree from Northwestern University Medical School in 1970, and a degree in Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine in 1980. After serving his residency at Cleveland Metropolitan General Hospital, he was a fellow in infectious disease at WRAIR. He is a professor of clinical medicine at the University of North Carolina at Chapel Hill and serves as a reviewer on many leading medical journals in infectious disease.